AR022423A1 - Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento - Google Patents
Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamentoInfo
- Publication number
- AR022423A1 AR022423A1 ARP000100323A ARP000100323A AR022423A1 AR 022423 A1 AR022423 A1 AR 022423A1 AR P000100323 A ARP000100323 A AR P000100323A AR P000100323 A ARP000100323 A AR P000100323A AR 022423 A1 AR022423 A1 AR 022423A1
- Authority
- AR
- Argentina
- Prior art keywords
- manufacture
- compounds derived
- acids
- hydroxamics
- benzodiazepina
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
Compuestos derivados de ácidos 2,3,4,5-tetrahidro-1H-[1,4]benzodiazepina-3-hidroxámicos que tienen la siguiente formula (1)en donde R1, R2, R3 R4 y R tienelos significados dados en la memoria descriptiva. Además se describen composiciones farmacéuticas que los comprenden y el uso de los mismos para la manufacturade un medicamento utiles en el tratamiento de condiciones de enfermedad mediadas por metaloproteinasas de matriz y TACE, tales como crecimiento de tumor,osteoartritis, artritis reumatoide y pérdida de cartílago degenerativa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23908099A | 1999-01-27 | 1999-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR022423A1 true AR022423A1 (es) | 2002-09-04 |
Family
ID=22900512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100323A AR022423A1 (es) | 1999-01-27 | 2000-01-26 | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1147095B1 (es) |
JP (1) | JP2002535392A (es) |
KR (1) | KR20010101730A (es) |
CN (1) | CN1197849C (es) |
AR (1) | AR022423A1 (es) |
AT (1) | ATE273288T1 (es) |
AU (1) | AU767039B2 (es) |
BG (1) | BG105736A (es) |
BR (1) | BR0007759A (es) |
CA (1) | CA2356267A1 (es) |
CZ (1) | CZ20012637A3 (es) |
DE (1) | DE60012883T2 (es) |
EA (1) | EA200100809A1 (es) |
ES (1) | ES2223470T3 (es) |
HU (1) | HUP0105302A3 (es) |
ID (1) | ID29046A (es) |
IL (1) | IL144168A0 (es) |
NO (1) | NO20013675L (es) |
NZ (1) | NZ511885A (es) |
PL (1) | PL349025A1 (es) |
PT (1) | PT1147095E (es) |
SK (1) | SK10422001A3 (es) |
TR (1) | TR200102131T2 (es) |
WO (1) | WO2000044730A1 (es) |
ZA (1) | ZA200104321B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2357110A1 (en) * | 2001-04-11 | 2002-10-11 | American Cyanamid Company | Method for the treatment of polycystic kidney disease |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
AU2002324716A1 (en) | 2001-08-17 | 2003-03-03 | Bristol-Myers Squibb Company Patent Department | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace) |
JP2005507937A (ja) | 2001-11-01 | 2005-03-24 | ワイス・ホールディングズ・コーポレイション | マトリックスメタロプロテイナーゼおよびtace阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸 |
US7488754B2 (en) | 2002-04-05 | 2009-02-10 | Wyeth | Method for the treatment of polycystic kidney disease |
JP2006501215A (ja) * | 2002-08-13 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体 |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
CA2526470A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Percussively ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
JP5069108B2 (ja) | 2004-07-21 | 2012-11-07 | メルク セローノ ソシエテ アノニム | オクタヒドロピロロ[2,3,c]ピリジン誘導体と、その医薬としての利用法 |
ATE509956T1 (de) * | 2006-06-08 | 2011-06-15 | Helmholtz Zentrum Muenchen | Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie |
EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
FR2950057B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2950056B1 (fr) | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
ES2592154T3 (es) | 2010-07-08 | 2016-11-28 | Kaken Pharmaceutical Co., Ltd. | Derivado de N-hidroxiformamida y medicamento que contiene el mismo |
CA2811504C (en) * | 2010-09-17 | 2018-06-05 | Kaken Pharmaceutical Co., Ltd. | Composition for maintaining function of platelets |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
CA3151199A1 (en) * | 2019-09-19 | 2021-03-25 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
CA2218503C (en) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
RU2164914C2 (ru) * | 1995-11-13 | 2001-04-10 | Хехст Акциенгезелльшафт | ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ |
BR9611929A (pt) * | 1995-12-08 | 1999-05-18 | Agouron Pharma | Inibidores de metaloproteinase composições farmacéuticas contendo os mesmos e seus usos farmacéuticos e métodos e intermediários úteis |
US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
NZ334253A (en) * | 1996-08-28 | 2000-11-24 | Procter & Gamble | N-hydroxy 1-[(4-methoxyphenyl)sulfonyl]-4-benzyloxycarbonyl-piperazine 2-carboxamide and derivatives thereof for treating musculoskeletal disease or cachexia |
HUP0000210A3 (en) * | 1996-08-28 | 2001-07-30 | Procter And Gamble Co Cincinna | Heterocyclic compounds as metalloprotease inhibitors and use of them for producing pharmaceutical compisitions |
CA2264266A1 (en) * | 1996-08-28 | 1998-03-05 | Neil Gregory Almstead | 1,3-diheterocyclic metalloprotease inhibitors |
KR20010034406A (ko) * | 1998-01-27 | 2001-04-25 | 아메리칸 사이아나미드 컴파니 | 매트릭스 메탈로프로테인아제 억제제로서의2,3,4,5-테트라하이드로-1h-[1,4]-벤조디아제핀-3-하이드록삼산 |
-
2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Application Discontinuation
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en active IP Right Grant
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 EP EP00909990A patent/EP1147095B1/en not_active Expired - Lifetime
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
-
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200104321B (en) | 2002-08-26 |
CN1337952A (zh) | 2002-02-27 |
AU3216000A (en) | 2000-08-18 |
HUP0105302A2 (hu) | 2002-07-29 |
DE60012883D1 (de) | 2004-09-16 |
HUP0105302A3 (en) | 2002-09-30 |
ES2223470T3 (es) | 2005-03-01 |
EP1147095B1 (en) | 2004-08-11 |
CN1197849C (zh) | 2005-04-20 |
AU767039B2 (en) | 2003-10-30 |
ID29046A (id) | 2001-07-26 |
NZ511885A (en) | 2003-06-30 |
ATE273288T1 (de) | 2004-08-15 |
SK10422001A3 (sk) | 2002-09-10 |
DE60012883T2 (de) | 2005-08-25 |
WO2000044730A1 (en) | 2000-08-03 |
KR20010101730A (ko) | 2001-11-14 |
PT1147095E (pt) | 2004-12-31 |
EA200100809A1 (ru) | 2002-02-28 |
NO20013675D0 (no) | 2001-07-26 |
TR200102131T2 (tr) | 2001-12-21 |
JP2002535392A (ja) | 2002-10-22 |
IL144168A0 (en) | 2002-05-23 |
BR0007759A (pt) | 2001-11-13 |
CA2356267A1 (en) | 2000-08-03 |
NO20013675L (no) | 2001-09-21 |
CZ20012637A3 (cs) | 2002-04-17 |
EP1147095A1 (en) | 2001-10-24 |
PL349025A1 (en) | 2002-07-01 |
BG105736A (en) | 2002-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
BR0009651A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas | |
AR023719A1 (es) | N-(glicilsustituidas)-2-ciano-pirrolidinas, una composicion farmaceutica y el uso de las mismas para la fabricacion de un medicamento | |
BR9916790A (pt) | Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente | |
DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
BR0210711A (pt) | Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto | |
BRPI0418006A (pt) | composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, e, combinação | |
AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
DE60239939D1 (de) | Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung | |
NO301419B1 (no) | 2-okso-5-oksazolidinmetylforbindelser, farmasöytiske preparater som inneholder slike, og anvendelse derav for fremstilling av legemidler | |
BR0212346A (pt) | Composto ou um sal farmaceuticamente aceitável, solvato, solvato deste sal ou uma pró-droga do mesmo, processo para a preparação do mesmo, uso deste, método para produzir um efeito inibidor de ibat em um animal de sangue quente, como um humano, em necessidade deste tratamento, e, composição farmacêutica | |
AR020662A1 (es) | Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento. | |
TR200003478T2 (tr) | Antikanser maddeleri olarak faydalı izotiyazol türevleri | |
BRPI0418004A (pt) | composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis, métodos para tratar ou prevenir condições hiperlipidêmicas, aterosclerose, mal de alzheimer, e tumores associados com colesterol, formulação farmacêutica, combinação, e, processo para preparar um composto ou um sal, solvato, solvato de um tal sal ou uma pró-droga deste farmaceuticamente aceitáveis | |
SE0103836D0 (sv) | Novel compounds | |
PT1263730E (pt) | Derivados amina para o tratamento de apoptose | |
ATE316083T1 (de) | Adamantanderivate | |
ATE235459T1 (de) | Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren | |
ATE350383T1 (de) | Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen | |
CL2004000965A1 (es) | Compuestos derivados de 2h-pirazol-3-il de formula definida, que actuan como inhibidores de quinasa p38 y tnf; composicion farmaceutica que comprende a uno de los compuestos; uso de la composicion en la preparacion de un medicamento; y uso de los com | |
DOP2003000678A (es) | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz | |
ES2168304T3 (es) | Derivados del taxol. | |
HUP0100520A1 (hu) | Csontfelszívódást és sejtösszenövést gátló új szulfonamidszármazékok | |
BR0315801A (pt) | Compostos piridopirimidinona, eu processo de preparação e as composições farmacêuticas que os contêm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |